Tag Archives: ML8500

Development of heat shock protein 90-targeted PDT for inflammatory breast cancer

Motivation of the study In photodynamic therapy (PDT), systemically administered photosensitizer is activated within the tumor using focused near-infrared light, typically a laser with a wavelength matching the absorption peak of the photosensitizer. Several photosensitizers have been clinically approved for the treatment of different cancers; however, their accumulation is non-tumor exclusive which exposes healthy tissues to side effects like daylight-induced phototoxicity. A promising strategy to improve tumor selectivity is to couple photosensitizer to a tumor-targeting agent that binds to a specific antigen expressed on the Continue reading →Customer case Research by: Duke University, founded in 1924, is one of the leading and wealthiest private research universities in the USA. The most notable Duke alumni is President Richard Nixon. Research at Duke University has been awarded with several Nobel prizes in recent years for groundbreaking discoveries in biochemistry and medicine, such as G-protein coupled receptors, DNA mismatch repair, and cellular regulation of hypoxia. Modulight products: ML8500, ML7710 (665 nm, 689 nm, 750 nm) Laser use: Heat shock protein 90-targeted PDT for breast cancer Continue reading →

In vitro illumination using ML8500: osmium-based anticancer photosensitizer with highest hypoxic activity reported to date

  Study protocol to determine wavelength, fluence, and irradiance activities of Os-4T:   Key observations Illumination parameters significantly affected the phototoxicity of Os-4T. The green light (525 nm) was more effective than the red light (630 nm) at lower fluences, while the maximal potency was achieved at both wavelengths when using fluences higher than 100 J/cm2. Irradiance affected the potency with both the red and the green light that were more effective when lower irradiances were used.   Graphs from the original publication. Open-access content Continue reading →Basic Info of the Study Research by: University of Texas at Arlington, US. One of the leading groups in photoactive drug discovery. Developed first clinical-level rubidium-based PS (TLD-1433), now in Theralase-sponsored Phase 2 trials for bladder cancer. Modulight products: ML8500 (445 nm, 525 nm, 630 nm, 753 nm, 810 nm) Laser use: Photoactive drug discovery Link to the study: Dr. Sherri McFarland (see her referral of Modulight) Research topics: Medicinal inorganic chemistry and drug discovery. Special interest in the synthesis of novel transition metal complexes and Continue reading →

Fully automated illumination study series for modern cancer drug development

Fully automated illumination study series for modern cancer drug development In vitro cell viability and dose escalation study for developing photosensitive or photoactivated drugs using Modulight ML7710 medical laser and ML8500 automated illumination system.     Experimental set up        Fully automated illumination study series for modern cancer drug development In vitro cell viability and dose escalation study for developing photosensitive or photoactivated drugs using Modulight ML7710 medical laser and ML8500 automated illumination system.   STUDY PLAN The goal was to investigate the effect of irradiance and light dose on a cancer cell line while keeping the photosensitive drug dosing constant. The well-by-well dose escalation plan was done in tabular format. TARGET Cancer cell line incubated at 37°C in acidic culture DRUG TYPE Photosensitive or Continue reading →